{
    "clinical_study": {
        "@rank": "4871", 
        "arm_group": {
            "arm_group_label": "Treatment (dabrafenib)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive dabrafenib PO BID on days 1-28 (QD on day 1 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial studies the side effects and the best dose of dabrafenib in treating\n      patients with solid tumors and kidney or liver dysfunction. Dabrafenib may stop the growth\n      of tumor cells by blocking some of the enzymes needed for cell growth."
        }, 
        "brief_title": "Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction", 
        "condition": [
            "Hepatic Complications", 
            "Renal Failure", 
            "Unspecified Adult Solid Tumor, Protocol Specific"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Renal Insufficiency", 
                "Liver Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the toxicity profile and the maximum tolerated doses (MTDs) of dabrafenib in\n      patients with v-raf murine sarcoma viral oncogene homolog B1 (BRAF)^V600X mutations and\n      renal or hepatic dysfunction.\n\n      SECONDARY OBJECTIVES:\n\n      I. To assess for tumor response and various times to clinical event. II. To provide dosing\n      recommendations for dabrafenib in patients with varying degrees of hepatic and renal\n      dysfunction for possible inclusion in the label.\n\n      TERTIARY OBJECTIVES:\n\n      I. To assess the pharmacokinetic and pharmacogenetic profile of dabrafenib and active\n      metabolites.\n\n      OUTLINE: This is a dose-escalation study.\n\n      Patients receive dabrafenib orally (PO) twice daily (BID) on days 1-28 (once daily [QD] on\n      day 1 of course 1). Courses repeat every 28 days in the absence of disease progression or\n      unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up at 30 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  PRE-REGISTRATION ELIGIBILITY CRITERIA\n\n          -  Willing to provide tissue as required per protocol for central BRAF-V600 mutation\n             testing\n\n               -  NOTE: Patients with prior BRAF testing that demonstrate a mutation at V600 will\n                  be allowed to enroll prior to central testing if the assay was performed at a\n                  Clinical Laboratory Improvement Amendments (CLIA)-certified lab using the COBAS,\n                  Pyromark BRAF, Karmonos Detroit Medical Center-University Laboratories (DMC)-UL\n                  BRAF, THxID BRAF or Response Genetics BRAF assays; if the assay was based on\n                  other methodology other than COBAS, Pyromark BRAF, Karmonos DMC-UL BRAF, THxID\n                  BRAF or Response Genetics BRAF assays, the results should be confirmed by\n                  central lab testing prior to patient enrollment; should central testing prove to\n                  be discordant with initial result (wild-type, non-mutated BRAF), patient will be\n                  allowed to continue on study at the discretion of the investigator\n\n          -  Patients with unknown BRAF status: histologically confirmed melanoma, papillary\n             thyroid, cholangiocarcinoma or testicular cancer that is metastatic or unresectable\n             and for which the investigator feels a BRAF targeted agent is a reasonable treatment\n\n               -  NOTE: patient must be screened by central BRAF testing and must demonstrate a\n                  V600 mutation prior to start of study agent\n\n               -  Note: other tumor types without known BRAF mutations will not be eligible for\n                  central testing\n\n          -  Ability to understand and willingness to sign written informed consent\n\n          -  Life expectancy of > 3 months\n\n          -  REGISTRATION ELIGIBILITY CRITERIA\n\n          -  Patients with known BRAF-V600 mutation: patients must have BRAF-V600 mutated,\n             histologically confirmed cancer that is metastatic or unresectable and for which\n             curative or standard therapies do not exist or are no longer effective\n\n               -  NOTE: Colorectal cancers with BRAF mutations ARE NOT allowed\n\n               -  NOTE: Any mutation at the V600 position that results in a change from V (valine)\n                  is allowed; this includes E, D, K, R or other mutations not noted here at the\n                  V600 position\n\n          -  Any number of the following prior therapies is allowed:\n\n               -  Chemotherapy >= 28 days prior to registration\n\n               -  Mitomycin C/nitrosoureas >= 42 days prior to registration\n\n               -  Immunotherapy >= 28 days prior to registration\n\n               -  Biologic therapy >= 28 days prior to registration\n\n               -  Radiation therapy >= 28 days prior to registration\n\n               -  Radiation to < 25% of bone marrow\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Karnofsky >=\n             70%)\n\n          -  Able to swallow and retain oral medication\n\n          -  Absolute neutrophil count (ANC) >= 1.5 x 10^9/L\n\n          -  Hemoglobin >= 9 g/dL\n\n          -  Platelets >= 75 x 10^9/L\n\n          -  Hepatic and renal function meeting one of the strata below:\n\n               -  Group N: Hepatic: normal function (bilirubin =< upper limit of normal [ULN];\n                  aspartate aminotransferase [AST] =< ULN); Renal: normal function (creatinine\n                  clearance [CrCl] >= 60 mL/min)\n\n               -  Group R3: Hepatic: normal function (bilirubin =< ULN; AST =< ULN); Renal: severe\n                  dysfunction (CrCl >= 15 and < 30 mL/min)\n\n               -  Group R4: Hepatic: normal function (bilirubin =< ULN; AST =< ULN; Renal: renal\n                  failure (hemodialysis)\n\n               -  Group H1: Hepatic: mild dysfunction (bilirubin =< ULN; AST > ULN); Renal:\n                  acceptable function (CrCl >= 60 mL/min)\n\n               -  Group H2: Hepatic: moderate dysfunction (bilirubin > ULN and =< 3 x ULN; AST >\n                  ULN); Renal: acceptable function (CrCl>=\u2265 60 mL/min)\n\n               -  Group H3: Hepatic: severe dysfunction (bilirubin > 3 x ULN and up to\n                  investigators discretion; AST > ULN); Renal: acceptable function (CrCl >= 60\n                  mL/min)\n\n          -  Women of childbearing potential must have a negative serum pregnancy test =< 7 days\n             prior to registration\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (barrier method of birth control; abstinence) prior to study entry and for the\n             duration of study participation; should a woman become pregnant or suspect she is\n             pregnant while she or her partner is participating in this study, she should inform\n             her treating physician immediately; men treated or enrolled on this protocol must\n             also agree to use adequate contraception prior to the study, for the duration of\n             study participation, and 1 month after completion of dabrafenib administration\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n          -  Willingness to provide to provide blood and tissue samples as required per protocol\n\n          -  Patients with a history of clinical benefit from prior RAF inhibitor therapy, as\n             judged by the investigator, will be allowed\n\n        Exclusion Criteria:\n\n          -  Patients with active biliary obstruction; NOTE: patients for which a shunt has been\n             in place for at least 10 days prior to the first dose of dabrafenib are allowed\n\n          -  Reduced left ventricular ejection fraction (< 50%) or other evidence of cardiac\n             dysfunction as determined by the investigator\n\n          -  Use of an investigational anti-cancer drug within 28 days preceding the first dose of\n             dabrafenib\n\n          -  Patients receiving any medications or substances that are strong inhibitors or\n             inducers of cytochrome P450, family 3, subfamily A (CYP3A) or cytochrome P450 family\n             2, subfamily C, polypeptide 8 (CYP2C8) are ineligible\n\n               -  For patients on intermediate inducers or inhibitors, attempts should be made to\n                  switch to an alternative agent or delay enrollment until treatment course with\n                  concomitant agent completed; if not possible, patient may be enrolled if it is\n                  felt to be in the patients best interest as decided by the investigator\n\n               -  Weak inhibitors of CYP3A or CYP2C8 should be used with caution and attempts made\n                  to limit their use or find alternative agents, if possible\n\n          -  Warfarin use is provisionally allowed\n\n          -  Unresolved toxicity of National Cancer Institute Common Terminology Criteria for\n             Adverse Events, version 4.0 (NCI CTCAE v4.0) grade 2 or higher from previous\n             anti-cancer therapy, except alopecia\n\n          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral\n             therapy are ineligible; Note: patients not on antiretroviral therapies are eligible\n             for this study\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, diabetes mellitus, hypertension, symptomatic congestive heart failure,\n             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social\n             situations that would limit compliance with study requirements\n\n          -  Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection\n\n          -  Presence of malignancy other than the study indication under this trial within 5\n             years of study enrollment\n\n          -  Brain metastases that are symptomatic or untreated or not stable for >= 3 months\n             (must be documented by imaging) or requiring corticosteroids; subjects on a stable\n             dose of corticosteroids > 1 month or who have been off corticosteroids for at least 2\n             weeks can be enrolled with approval of the Cancer Therapy Evaluation Program (CTEP)\n             medical monitor; subjects must also be off enzyme-inducing anticonvulsants for > 4\n             weeks\n\n          -  History of acute coronary syndromes (including unstable angina), coronary\n             angioplasty, or stenting within the past 24 weeks; class II, III, or IV heart failure\n             as defined by the New York Heart Association (NYHA) functional classification system;\n             or history of known cardiac arrhythmias unless it has been stably controlled\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to dabrafenib or other agents used in this study\n\n          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if\n             the mother is treated with dabrafenib\n\n          -  Any condition or medical problem in addition to the underlying malignancy and organ\n             dysfunction which the investigator feels would pose unacceptable risk"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "122", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01907802", 
            "org_study_id": "NCI-2013-01338", 
            "secondary_id": [
                "NCI-2013-01338", 
                "MC1211", 
                "9343", 
                "U01CA132123", 
                "U01CA069912", 
                "P30CA015083"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (dabrafenib)", 
                "description": "Given PO", 
                "intervention_name": "dabrafenib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BRAF inhibitor GSK2118436", 
                    "GSK-2118436A", 
                    "GSK2118436", 
                    "Tafinlar"
                ]
            }, 
            {
                "arm_group_label": "Treatment (dabrafenib)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }, 
            {
                "arm_group_label": "Treatment (dabrafenib)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "vchung@coh.org", 
                    "last_name": "Vincent Chung", 
                    "phone": "626-471-9200"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope"
                }, 
                "investigator": {
                    "last_name": "Vincent Chung", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "elkhouei@med.usc.edu", 
                    "last_name": "Anthony El-Khoueiry", 
                    "phone": "323-865-3595"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "University of Southern California/Norris Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Anthony El-Khoueiry", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "karen.kelly@ucdmc.ucdavis.edu", 
                    "last_name": "Karen L. Kelly", 
                    "phone": "916-734-3735"
                }, 
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "University of California at Davis Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Karen L. Kelly", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "skoehler@cohmg.com", 
                    "last_name": "Stephen C. Koehler", 
                    "phone": "626-396-2900"
                }, 
                "facility": {
                    "address": {
                        "city": "South Pasadena", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91030"
                    }, 
                    "name": "City of Hope South Pasadena"
                }, 
                "investigator": {
                    "last_name": "Stephen C. Koehler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cindy.obryant@ucdenver.edu", 
                    "last_name": "Cindy O'Bryant", 
                    "phone": "303-724-2625"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado Cancer Center - Anschutz Cancer Pavilion"
                }, 
                "investigator": {
                    "last_name": "Cindy O'Bryant", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kim.george@mayo.edu", 
                    "last_name": "George P. Kim", 
                    "phone": "904-953-6460"
                }, 
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32224-9980"
                    }, 
                    "name": "Mayo Clinic in Florida"
                }, 
                "investigator": {
                    "last_name": "George P. Kim", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mrudek2@jhmi.edu", 
                    "last_name": "Michelle A. Rudek", 
                    "phone": "410-614-6321"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins University/Sidney Kimmel Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Michelle A. Rudek", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "geoffrey_shapiro@dfci.harvard.edu", 
                    "last_name": "Geoffrey I. Shapiro", 
                    "phone": "617-632-4942"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Geoffrey I. Shapiro", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lorussop@karmanos.org", 
                    "last_name": "Patricia M. LoRusso", 
                    "phone": "313-576-8716"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Barbara Ann Karmanos Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Patricia M. LoRusso", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "haluska.paul@mayo.edu", 
                    "last_name": "Paul Haluska", 
                    "phone": "507-284-2511"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Paul Haluska", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jennifer.eads@uhhospitals.org", 
                    "last_name": "Jennifer R. Eads", 
                    "phone": "216-844-6031"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Case Western Reserve University"
                }, 
                "investigator": {
                    "last_name": "Jennifer R. Eads", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tawbhx@upmc.edu", 
                    "last_name": "Hussein A. Tawbi", 
                    "phone": "412-648-6578"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15232"
                    }, 
                    "name": "University of Pittsburgh"
                }, 
                "investigator": {
                    "last_name": "Hussein A. Tawbi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "wrs@medicine.wisc.edu", 
                    "last_name": "William R. Schelman", 
                    "phone": "608-263-6222"
                }, 
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792"
                    }, 
                    "name": "University of Wisconsin Hospital and Clinics"
                }, 
                "investigator": {
                    "last_name": "William R. Schelman", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "philippe.bedard@unh.ca", 
                    "last_name": "Philippe L. Bedard", 
                    "phone": "416-946-4534"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "University Health Network-Princess Margaret Hospital"
                }, 
                "investigator": {
                    "last_name": "Philippe L. Bedard", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 and Pharmacokinetic Study of Dabrafenib (GSK2118436B) in Patients With BRAFV600X Mutations and Renal or Hepatic Dysfunction", 
        "other_outcome": [
            {
                "description": "Descriptive statistics and statistical plots will form the basis of presentation of biomarker, pharmacokinetic and pharmacogenetic studies. Clinical response and toxicity profile for patients will be correlated with the pharmacokinetic (PK) parameters and key polymorphisms in gene.", 
                "measure": "Pharmacokinetic profile of dabrafenib", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 15 of course 1, and day 1 of all subsequent courses"
            }, 
            {
                "description": "Descriptive statistics and statistical plots will form the basis of presentation of biomarker, pharmacokinetic and pharmacogenetic studies. Clinical response and toxicity profile for patients will be correlated with the PK parameters and key polymorphisms in gene.", 
                "measure": "Pharmacogenetic profile of dabrafenib", 
                "safety_issue": "No", 
                "time_frame": "Day 1 prior to treatment"
            }
        ], 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Paul Haluska", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Overall toxicity incidence as well as toxicity profiles by dose level and patient will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.", 
                "measure": "Incidence of toxicities graded according to NCI CTCAE v4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after completion of study treatment"
            }, 
            {
                "description": "Overall toxicity incidence as well as toxicity profiles by dose level and patient will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.", 
                "measure": "MTD of dabrafenib, defined as the highest dose level that is estimated to induce a dose-limiting toxicity (DLT) rate less than 33.3% by the two-way isotonic regression, graded according to NCI CTCAE v4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01907802"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The number and severity of all adverse events (overall, by dose level, and by tumor group) will be tabulated and summarized for the three patient groups. The grade 3+ adverse events will also be described and summarized in a similar fashion.", 
                "measure": "Incidence of adverse events graded according to NCI CTCAE v4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after completion of study treatment"
            }, 
            {
                "description": "Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease.", 
                "measure": "Best response, defined as the best objective status recorded from the start of treatment until disease progression/recurrence, measured by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 days after completion of study treatment"
            }, 
            {
                "description": "The data on time-related variables will be summarized descriptively.", 
                "measure": "Time until any treatment-related toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after completion of study treatment"
            }, 
            {
                "description": "The data on time-related variables will be summarized descriptively.", 
                "measure": "Time until treatment related grade 3+ toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after completion of study treatment"
            }, 
            {
                "description": "The data on time-related variables will be summarized descriptively.", 
                "measure": "Time until hematologic nadirs (white blood cells [WBC], ANC, platelets)", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 days after completion of study treatment"
            }, 
            {
                "description": "The data on time-related variables will be summarized descriptively.", 
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 days after completion of study treatment"
            }, 
            {
                "description": "The data on time-related variables will be summarized descriptively.", 
                "measure": "Time to treatment failure", 
                "safety_issue": "No", 
                "time_frame": "Time from registration to documentation of progression, unacceptable toxicity, or refusal to continue participation by the patient, assessed up to 30 days after completion of study treatment"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}